Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients with chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
Study identifier:BY217/M2-110
ClinicalTrials.gov identifier:NCT00062582
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
Phase 3
Healthy volunteers
No
Study drug
Roflumilast
Sex
All
Actual Enrollment
1000
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 2003
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
